Nutriband Receives Patent Notice of Publication for its Abuse Deterrent Transdermal Technology
Nutriband Inc. recently announced it has received a Notice of Publication of the Registration and Grant of a Standard Patent (R) from the Hong Kong Intellectual Property Department for patent application titled Abuse and Misuse Deterrent Transdermal Systems,” which protects its AVERSA abuse deterrent transdermal technology.
The Hong Kong Patents Registrar has assigned Publication Number 40085268 B to the patent with a publication date of December 20, 2024. Hong Kong is a Special Administrative Region (SAR) of the People’s Republic of China which affords it a high degree of autonomy with its own patent system and patent laws which are separate and distinct from those of mainland China.
The Aversa abuse deterrent technology is now covered by a broad international intellectual property portfolio with patents issued in 46 countries including the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.
Nutriband’s AVERSA abuse deterrent technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential including opioids and stimulants. The AVERSA abuse deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse while making sure that these drugs remain accessible to those patients who really need them.
Nutriband abuse deterrent transdermal technology consists of a proprietary aversive agent coating that employs taste aversion to deter the oral abuse of and accidental exposure to transdermal opioid and stimulant patch products. Preliminary studies have shown that the coating is very difficult to scrape off and the technology has a patented immediate and extended-release profile which presents an additional layer of deterrence to prevent the aversive layer from easily being washed off in an attempt to separate the drug from the aversive agents.
Nutriband is currently working with its partner Kindeva Drug Delivery, a leading global contract development and manufacturing organization focused on drug-device combination products, to develop its lead product, AVERSA Fentanyl, which incorporates Nutriband’s AVERSA abuse deterrent transdermal technology into Kindeva’s FDA-approved transdermal fentanyl patch system.
AVERSA Fentanyl has the potential to be the world’s first abuse deterrent opioid patch designed to deter the abuse and misuse and reduce the risk of accidental exposure of transdermal fentanyl patches. AVERSA Fentanyl has the potential to reach peak annual US sales of $80 million to $200 million.
Nutriband’s AVERSA abuse deterrent transdermal technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The AVERSA abuse deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible to those patients who really need them. The technology is covered by a broad intellectual property portfolio with patents granted in the US, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.
Nutriband Inc. is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse deterrent fentanyl patch incorporating our AVERSA abuse deterrent technology. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. For more information, visit www.nutriband.com.
Total Page Views: 311